^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Prostate Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur Urol Oncol
    Title:

    Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis

    Published date:
    09/16/2023
    Excerpt:
    The single-arm OS and PFS analyses revealed similarities among different PARPis; pooled PFS and OS medians were 9.7 mo (CI: 8.1–12.5) and 17.4 mo (CI: 12.7–20.1), respectively….Our data revealed that different PARPis were similarly effective in terms of PFS and OS. Moreover, we found that PARPi and platinum therapy were comparable in terms of PSA50 response rate and OS, highlighting that platinum is a valid treatment option for BRCA-positive mCRPC patients.
    DOI:
    https://doi.org/10.1016/j.euo.2023.09.001
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur Urol
    Title:

    When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials

    Published date:
    08/17/2020
    Excerpt:
    Emerging data suggest that the greatest efficacy with single-agent PARP inhibitors is seen in mCRPC patients with germline or somatic BRCA1/2 alterations (especially BRCA2 or biallelic mutations), with potential efficacy also observed in men with PALB2 and FANCA mutations.
    DOI:
    10.1016/j.euo.2020.07.005